Nucleic acid therapies: AAV-based epigenetic perturbation - from translational disease models to anti-arrhythmic strategies
| Institution | Universität Heidelberg |
|---|---|
| Project leader | Ralf Gilsbach |
| Site | Heidelberg/Mannheim |
| Project type | Innovation Cluster |
| Funding | € 775.185,00 |
| Begin | 01.11.2023 |
| End | 31.10.2026 |
| Partnerprojekte |
Förderkennzeichen
81X4500124
Projektnummer
1802